10-Q · May 15, 2026
AIM ImmunoTech's Q1 2026 results revealed total revenue of $16 million, significantly below the consensus estimate of $134.3 million, while reporting an EPS of -0.05, slightly better than the expected -0.17. The company…
Earnings analysis · 10-Q
AIM earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text does not include the income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A financial trends, so current-quarter revenue, margins, EPS, liquidity, and free cash flow…
Read full summary
The extracted 10-Q text does not include the income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A financial trends, so current-quarter revenue, margins, EPS, liquidity, and free cash flow cannot be assessed from the available filing content. The principal disclosed update is substantial equity financing: approximately $10.4 million of gross proceeds during the six months ended June 30, 2026, alongside approximately 48.5 million warrants outstanding. Management specifically warns that warrant exercise or future capital raises may cause significant dilution, supporting a bearish risk assessment.
What stood out
-
Raised $10.4M Through Equity Transactions
The company completed multiple equity transactions during the six months ended June 30, 2026, raising approximately $10.4 million in aggregate gross proceeds. The transactions included a rights offering, inducement transactions, and registered direct offerings.
-
48.5M Warrants Outstanding
The filing identifies approximately 48.5 million warrants outstanding as of June 30, 2026, providing potential future capital if exercised, although the filing emphasizes associated dilution risk.
What to watch
-
Substantial Shareholder Dilution
During the six months ended June 30, 2026, equity transactions raised approximately $10.4 million but resulted in issuance of a substantial number of common shares, preferred shares, and warrants. Approximately 48.5 million warrants were outstanding as of June 30, 2026; full exercise could significantly dilute existing stockholders and sales of the underlying shares could depress the stock price.
Management's outlook
No quantitative revenue or EPS outlook is provided in the extracted 10-Q text; the filing does not state that prior guidance was raised, maintained, lowered, or withdrawn.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.